Lumonus has raised A$25 million in a Series B financing round to expand the global reach and product capabilities of its AI-powered radiation oncology workflow platform. The round was led by Aviron Investment Management with continued participation from Oncology Ventures, reflecting growing clinical adoption of Lumonus AI across health systems in the United States, Australia, and Europe.
The Lumonus platform has already supported clinicians in consulting and prescribing over 280,000 cancer treatments, and has automated the creation of more than 75,000 treatment plans. The company’s product suite is used in routine clinical environments to address workflow bottlenecks in cancer care delivery and to improve quality and operational efficiency.
Lumonus’ leadership team comprises professionals with over a century of combined clinical, operational, and technical experience across major cancer centers worldwide. The company’s approach is anchored in close collaboration with cancer care teams and a focus on solving real challenges that affect treatment speed, precision, and consistency.
The new funding will be allocated to expanding U.S. commercial and clinical success teams, advancing the Lumonus AI Physician and Lumonus AI Dosimetry product lines, and scaling clinical informatics work to support personalized and data-driven oncology care. The company also plans to deepen its partnerships with health systems to support quality measurement, operational performance improvement, and real-world evidence initiatives.
Lumonus continues to expand its presence across the United States, Australia, and Europe, positioning its AI-native oncology infrastructure as a foundational technology layer to enhance clinical delivery in cancer treatment environments.
KEY QUOTES
“Oncology is at an inflection point. Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace. By combining AI-native architecture, a comprehensive end-to-end workflow approach, and a commitment to partnering with care teams to solve real-world pain points, we are reimagining oncology workflows. This investment allows us to expand our world-class team and support more health systems that are ready to embrace a better way.”
Keith Hansen, Chief Executive Officer of Lumonus
“This milestone reflects the dedication of our entire team, who have worked side by side with clinicians worldwide to demonstrate real impact in oncology today and to show what the future of cancer care can be. Our unique AI-native platform has already demonstrated its ability to improve clinical quality and operational efficiency. This new capital will allow us to accelerate both product innovation and expand our U.S. commercial footprint.”
Merrick Howes, Chairman of Lumonus
“The Lumonus team combines deep clinical expertise with world-class product execution and has already earned the trust of leading cancer centers internationally. We are proud to support Lumonus as they continue to deliver measurable impact and set the standard for the future of oncology workflows.”
Ben Freeberg, Managing Partner at Oncology Ventures
